9,364 Shares in Enovis Corporation $ENOV Bought by Fiduciary Financial Group LLC

Key Points

• Fiduciary Financial Group LLC has acquired 9,364 shares of Enovis Corporation, valued at approximately $309,000, during the second quarter according to their latest SEC filing.
• Enovis reported earnings of $0.79 per share, beating analyst expectations, with a revenue of $564.5 million for the last quarter, marking a 7.5% increase year-over-year.
• CEO Damien McDonald increased his holdings by acquiring 6,457 shares, while several research firms have adjusted their price targets, with a consensus target now set at $51.00.

Fiduciary Financial Group LLC purchased a new stake in shares of Enovis Corporation (NYSE:ENOV - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 9,364 shares of the company's stock, valued at approximately $309,000.

Other hedge funds have also recently made changes to their positions in the company. US Bancorp DE raised its stake in Enovis by 2.5% during the 1st quarter. US Bancorp DE now owns 19,031 shares of the company's stock valued at $727,000 after purchasing an additional 462 shares during the period. CSS LLC IL purchased a new stake in Enovis during the 4th quarter valued at approximately $434,000. Stonegate Investment Group LLC purchased a new stake in Enovis during the 1st quarter valued at approximately $237,000. State of Alaska Department of Revenue raised its position in shares of Enovis by 394.4% during the first quarter. State of Alaska Department of Revenue now owns 31,504 shares of the company's stock valued at $1,203,000 after buying an additional 25,132 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Enovis by 72.9% in the first quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the company's stock worth $1,024,000 after buying an additional 11,300 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Stock Up 0.7%

Shares of NYSE:ENOV opened at $31.80 on Friday. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -2.23 and a beta of 1.68. Enovis Corporation has a 12 month low of $25.47 and a 12 month high of $49.83. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53. The company has a 50-day moving average price of $29.85 and a 200 day moving average price of $32.71.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. The business had revenue of $564.50 million for the quarter, compared to the consensus estimate of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.62 earnings per share. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, equities research analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Activity at Enovis

In other news, CEO Damien Mcdonald acquired 6,457 shares of the business's stock in a transaction on Thursday, September 11th. The shares were acquired at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the transaction, the chief executive officer directly owned 102,753 shares of the company's stock, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average price of $29.71 per share, with a total value of $74,275.00. Following the acquisition, the chief financial officer directly owned 116,729 shares in the company, valued at approximately $3,468,018.59. The trade was a 2.19% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 12,157 shares of company stock worth $374,760. Company insiders own 2.70% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on ENOV. Wells Fargo & Company cut their target price on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. UBS Group cut their price objective on Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Canaccord Genuity Group decreased their target price on Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Evercore ISI dropped their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Finally, Needham & Company LLC cut their price target on Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $51.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.